On September 25, 2018 LabCorp (NYSE: LH) reported that it will release its third quarter 2018 financial results before the market opens on Wednesday, October 24, 2018, and then will host a conference call and webcast beginning at 9:00 a.m. EDT to discuss the results (Press release, LabCorp, SEP 25, 2018, View Source;p=RssLanding&cat=news&id=2368816 [SID1234529635]). The earnings release and accompanying financial information will be posted on the LabCorp Investor Relations website.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Interested parties can access the conference call in listen-only mode by dialing 844-634-1444 within the U.S. and Canada, or 1-615-247-0253 internationally, using the passcode 7398818. In addition, a real-time webcast of the conference call will be available on the LabCorp Investor Relations website.

An audio replay of the conference call will be available from 1:00 p.m. EDT on October 24, 2018, until 11:30 a.m. EDT on November 7, 2018, by dialing 855-859-2056 within the U.S. and Canada, or 1-404-537-3406 internationally, using the passcode 7398818. The webcast of the conference call will be archived and accessible through October 18, 2019, on the LabCorp Investor Relations website.

On September 25, 2018 BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) reported that the company will present at the Cantor Fitzgerald Global Healthcare Conference in New York on Tuesday, October 2, 2018 at 1:40 p.m. ET (Press release, BioCryst Pharmaceuticals, SEP 25, 2018, View Source [SID1234529659]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Links to a live audio webcast and replay of this presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

On September 25, 2018 Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of cancer, reported that William G. Rice, Chairman, Ph.D., President and Chief Executive Officer, and Gregory K. Chow, Senior Vice President and Chief Financial Officer, will participate at the following upcoming conferences (Press release, Aptose Biosciences, SEP 25, 2018, View Source [SID1234529657]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

2018 Cantor Fitzgerald Global Healthcare Conference
Date: Tuesday, October 2, 2018
Time: 8:00 a.m. EDT
Format: Company Presentation
Location: Intercontinental New York Barclay Hotel, New York City
Live webcast: Cantor Fitzgerald Conference Webcast Link

·Leerink Partners Roundtable Series: Rare Disease & Oncology
Date: Wednesday, October 3, 2018
Time: 2:00 p.m. EDT
Format: Fireside Chat
Location: Lotte New York Palace Hotel, New York City
Live webcast: Leerink Partners Conference Webcast Link

·18th Annual Biotech in Europe Forum
Date: Friday, October 5, 2018
Location: Centre Congress, Basel, Switzerland

9:45 a.m. CEST – Company Presentation
12:10 p.m. CEST – Oncology II – Advanced Therapeutics Panel

The live webcasts can also be accessed through the Aptose website at www.aptose.com and will be archived shortly after the live event and available for 90 days.

On September 25, 2018 Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, reported that members of the Company’s management team will participate in the following upcoming investor conferences (Press release, Karyopharm, SEP 25, 2018, View Source [SID1234529570]):

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The Cantor Fitzgerald Global Healthcare Conference on Tuesday, October 2, 2018 at 2:50 p.m. ET.

The Leerink Partners Roundtable Series: Rare Disease & Oncology on Wednesday, October 3, 2018 at 9:00 a.m. ET.
A live webcast of each of these events will be available on the "Events & Presentations" page in the Investors section of the Company’s website at View Source A replay of each webcast will be archived on the Company’s website for 90 days following the presentation.

On September 25, 2018 Protagen AG, the National Center for Tumor Diseases (NCT) and NEC Laboratories Europe GmbH have reported a collaboration to improve the in silico prediction of immunotherapy response in malignant melanoma (Press release, Protagen, SEP 25, 2018, View Source [SID1234529620]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Cancer immunotherapy, e.g. by Checkpoint inhibitors, offers enormous potential for the treatment of many cancer indications, including melanoma. Although stimulation of the immune system holds great promise for cancer treatment, many challenges remain, including a limited response rate and even resistance in some patients. Also, patients may suffer from severe immune-related adverse events (irAEs), resulting from an overactivated immune response. Both the variable clinical response and irAEs demand predictive models to support patient management.

Through this collaboration, Protagen, NCT and NEC will develop and apply deep machine-learning to explore and establish biomarker models for relevant treatment-associated endpoints such as irAEs, clinical response, and/or survival.

Dr. Saverio Niccolini, General Manager, NEC Laboratories Europe commented: "The field of machine learning and AI has witnessed dramatic progress over the last decade and will soon be a critical component for the analysis of patient data. Extensive biomarker guidance will be required to allocate patients to the most appropriate clinical trial and – after approval of novel treatments – deliver the best therapy to each patient. We would like to be involved in this process and look forward to the collaboration with the NCT and Protagen."

PD Dr. Jessica Hassel from the NCT, stated: "Checkpoint inhibitors offer an enormous potential but also provide some challenges. Building on our initial collaboration with Protagen, we see this project as an opportunity to address the challenges posed by limited response rates and irAEs utilizing machine learning and AI. Although to date its impact remains low, we are convinced that from the molecular characterization of tumors to personalized treatment, machine learning will be increasingly important, hence we look forward to this collaboration."

Dr. Georg Lautscham, Protagen’s CEO, added: "Immunotherapies are a new cornerstone in treating cancer patients. An important challenge is to understand which patients are most likely to respond or suffer from irAEs. Protagen has developed an immuno-profiling approach and machine learning strategies to deal with highly dimensional patient data to address this. We are convinced machine learning efforts will increasingly influence the field, and are excited that NEC and NCT share this view and look forward to advancing this approach together."